• Aliases: BIOMAb EGFR, Theraloc, Thera-CIM-hr3, CIMAher, OSAG 101
    • A humanized IgG1 monoclonal antibody that binds to and inhibits EGFR
    • Currently in phase 2 and 3 studies with NSCLC, esophageal, head and neck, ovarian, rectal, gastric, and breast cancers
    • Approved drug in Argentina, China, Colombia, Cuba, and India for indications of SCCHN cancer, glioma, and esophageal cancer
    • Approved dose: 200 mg IV every week in conjunction with radiation; doses up to 800 mg for monotherapy proven safe in phase 1 clinical trials
    • Half-life: A range of 34 to 75 hours (increased ose from 100 to 400 mg)
    Other topics in Targeted and Immunotherapy Agents